FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308018566> ?p ?o ?g. }

• W4308018566 abstract "To evaluate the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus and Enterococcus species isolates were collected as part of the China Antimicrobial Surveillance Network (CHINET) in 2019 to provide susceptibility data for Staphylococcus spp. and Enterococcus spp. for their future development and application in clinical practice. Antimicrobial susceptibility testing was performed using the CLSI broth microdilution reference method. Eravacycline was highly active against Staphylococcus and Enterococcus species isolates, proved by the MIC50/90: 0.06/0.125, 0.06/0.25, 0.06/0.25, 0.06/0.25, 0.125/0.5, 0.125/0.25, and 0.03/0.06 mg/L for Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), S. epidermidis, S. hominis, S. haemolyticus, Enterococcus faecalis, and E. faecium, respectively. S. aureus isolates tested were fully susceptible to tedizolid. Still, nonsusceptible isolates were found for E. faecalis (72/567 [12.7%]) and E. faecium (12/501 [2.4%]). Norvancomycin at 2 mg/L could inhibit 100% of Staphylococcus spp., while 1 mg/L of ceftaroline could inhibit 78.9% of MRSA and 99.9% of methicillin-susceptible S. aureus (MSSA) isolates. Additionally, nemonoxacin was also active against Staphylococcus and Enterococcus species isolates tested (shown by the following MIC90s and ranges, in milligrams per liter: 2 and ≤0.015 to 8 for MRSA, 0.25 and ≤0.015 to 4 for MSSA, 0.5 and ≤0.015 to 8 for S. epidermidis, and 4 and ≤0.015 to >32 for E. faecalis). In conclusion, both eravacycline and tedizolid were highly active against clinical isolates of Staphylococcus spp. and Enterococcus spp. recently collected across China. Nemonoxacin showed potent activity against Staphylococcus spp. and E. faecalis but limited activity against E. faecium. Norvancomycin and ceftaroline displayed highly potent activity against Staphylococcus spp. IMPORTANCE Antimicrobial resistance has become a severe threat to global public health. According to statistics, nearly 700,000 people die from bacterial infections worldwide (J. O'Neill, Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, 2014; C. Y. Chin, K. A. Tipton, M. Farokhyfar, E. M. Burd, et al., Nat Microbiol 3:563-569, 2018, https://doi.org/10.1038/s41564-018-0151-5). The number of bacterial infections is expected to climb to 10 million by 2050, showing that bacterial resistance has become a significant problem that cannot be ignored. It is crucial to develop new antimicrobial agents to combat antimicrobial-resistant bacteria. In this study, we evaluated the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus spp. and Enterococcus species isolates which were collected as part of CHINET in 2019. We believe that this study can provide susceptibility data for Staphylococcus spp. and Enterococcus spp. for their future development and application in clinical practice." @default.
• W4308018566 created "2022-11-07" @default.
• W4308018566 creator A5001950064 @default.
• W4308018566 creator A5002139648 @default.
• W4308018566 creator A5003261759 @default.
• W4308018566 creator A5003596085 @default.
• W4308018566 creator A5004003302 @default.
• W4308018566 creator A5004412369 @default.
• W4308018566 creator A5006822602 @default.
• W4308018566 creator A5007513762 @default.
• W4308018566 creator A5010333596 @default.
• W4308018566 creator A5012873527 @default.
• W4308018566 creator A5013137065 @default.
• W4308018566 creator A5013155691 @default.
• W4308018566 creator A5015356988 @default.
• W4308018566 creator A5016765177 @default.
• W4308018566 creator A5018050306 @default.
• W4308018566 creator A5018229881 @default.
• W4308018566 creator A5021023077 @default.
• W4308018566 creator A5021056558 @default.
• W4308018566 creator A5021696894 @default.
• W4308018566 creator A5021827773 @default.
• W4308018566 creator A5022216408 @default.
• W4308018566 creator A5022312478 @default.
• W4308018566 creator A5023669066 @default.
• W4308018566 creator A5024076429 @default.
• W4308018566 creator A5024436877 @default.
• W4308018566 creator A5024586041 @default.
• W4308018566 creator A5024602024 @default.
• W4308018566 creator A5026192010 @default.
• W4308018566 creator A5026683899 @default.
• W4308018566 creator A5029636776 @default.
• W4308018566 creator A5030777635 @default.
• W4308018566 creator A5030968272 @default.
• W4308018566 creator A5031394968 @default.
• W4308018566 creator A5032109840 @default.
• W4308018566 creator A5033223088 @default.
• W4308018566 creator A5035340974 @default.
• W4308018566 creator A5035772565 @default.
• W4308018566 creator A5036214781 @default.
• W4308018566 creator A5036371038 @default.
• W4308018566 creator A5036457690 @default.
• W4308018566 creator A5036719672 @default.
• W4308018566 creator A5038837596 @default.
• W4308018566 creator A5039751965 @default.
• W4308018566 creator A5040515078 @default.
• W4308018566 creator A5040641714 @default.
• W4308018566 creator A5041370652 @default.
• W4308018566 creator A5042622182 @default.
• W4308018566 creator A5044794520 @default.
• W4308018566 creator A5045297327 @default.
• W4308018566 creator A5046532534 @default.
• W4308018566 creator A5047160347 @default.
• W4308018566 creator A5047321073 @default.
• W4308018566 creator A5047343672 @default.
• W4308018566 creator A5047787213 @default.
• W4308018566 creator A5049692788 @default.
• W4308018566 creator A5051043108 @default.
• W4308018566 creator A5052152702 @default.
• W4308018566 creator A5053969245 @default.
• W4308018566 creator A5054081107 @default.
• W4308018566 creator A5054352845 @default.
• W4308018566 creator A5055450266 @default.
• W4308018566 creator A5055513496 @default.
• W4308018566 creator A5056796466 @default.
• W4308018566 creator A5057457548 @default.
• W4308018566 creator A5059415743 @default.
• W4308018566 creator A5061266325 @default.
• W4308018566 creator A5062447307 @default.
• W4308018566 creator A5063383376 @default.
• W4308018566 creator A5063983834 @default.
• W4308018566 creator A5064410725 @default.
• W4308018566 creator A5064842058 @default.
• W4308018566 creator A5064888892 @default.
• W4308018566 creator A5068480931 @default.
• W4308018566 creator A5068764583 @default.
• W4308018566 creator A5069639288 @default.
• W4308018566 creator A5069849278 @default.
• W4308018566 creator A5072080566 @default.
• W4308018566 creator A5072945846 @default.
• W4308018566 creator A5074942308 @default.
• W4308018566 creator A5075012844 @default.
• W4308018566 creator A5077890299 @default.
• W4308018566 creator A5078662709 @default.
• W4308018566 creator A5081884581 @default.
• W4308018566 creator A5081922458 @default.
• W4308018566 creator A5082136602 @default.
• W4308018566 creator A5084940267 @default.
• W4308018566 creator A5085822601 @default.
• W4308018566 creator A5087032974 @default.
• W4308018566 creator A5087270087 @default.
• W4308018566 date "2022-12-21" @default.
• W4308018566 modified "2023-09-27" @default.
• W4308018566 title "Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 <i>Staphylococcus</i> and 1,068 <i>Enterococcus</i> Species Isolates from China: Updated Report of the CHINET Study 2019" @default.
• W4308018566 cites W1591477834 @default.
• W4308018566 cites W2146157756 @default.
• W4308018566 cites W2155269185 @default.
• W4308018566 cites W2312720395 @default.
• W4308018566 cites W2314649741 @default.
• W4308018566 cites W2739642249 @default.

• next